Who Paid My Doc Search
Menu
Product Program year 2020 Source: CMS Open Payments

Voraxaze

Drug Toxicity Antidote Methotrexate Toxicity

NDC 50633-210-11

Open in the dashboard

General payments

$222,268

276 payments

Research payments

$373,678

8 payments

Through program year 2020, $222,268 in general payments and $373,678 in research payments were reported against Voraxaze (Toxicity Antidote Methotrexate Toxicity).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2020 Research $106,872 2
2019 General $222,268 276
2019 Research $266,806 6

Breakdown

Who paid General payments · program year 2019
  1. BTG International, Inc. $206,693 267 payments
  2. Biocompatibles, Inc. $15,576 9 payments
Top recipients General payments · program year 2019
  1. Scott Howard Pediatric Hematology-Oncology · Memphis, TN $58,502 26% · 6 payments
  2. Zeyad Kanaan Hematology & Oncology · Santa Rosa, CA $20,260 9% · 17 payments
  3. Anish Ray Pediatric Hematology-Oncology · Fort Worth, TX $17,034 8% · 34 payments
  4. Jaya Kala Nephrology · Houston, TX $16,953 8% · 25 payments
  5. Stephen Solomon Vascular & Interventional Radiology · New York, NY $12,288 6% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2019.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2019
  1. Pediatric Hematology-Oncology Pediatrics $101,717 48% · 17 practitioners
  2. Nephrology Internal Medicine $28,226 13% · 7 practitioners
  3. Neurology Psychiatry & Neurology $24,601 12% · 5 practitioners
  4. Hematology & Oncology Internal Medicine $20,811 10% · 31 practitioners
  5. Medical Oncology Internal Medicine $13,788 6% · 12 practitioners

The top 5 of 22 specialties; each share is of general payments naming this product to practitioners with a specialty in 2019. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2019
  1. Tennessee $58,527 26% · 2 recipients
  2. Texas $41,483 19% · 20 recipients
  3. California $21,352 10% · 11 recipients
  4. New York $17,469 8% · 5 recipients
  5. Washington $17,190 8% · 4 recipients

The top 5 of 27 states; each share is of general payments naming this product in 2019 where a state was reported.

The top 25 states, free in the app

Records

276 general · 8 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record